From the Wires
Cannabis Science Provides Corporate Guidance on Preclinical Initiatives and Recent Corporate Developments for its Shareholders; CBIS Announces plans for 1st Q of 2013 Webinar Investor Call
Recent Developments by Executive Management Preceding ballet initiative results of the 2012 Election, Positions Cannabis Science for the Development of its Initial Drug Pipeline
By: PR Newswire
Nov. 9, 2012 12:56 PM
COLORADO SPRINGS, Colo., Nov. 9, 2012 /PRNewswire/ -- Cannabis Science Inc., (OTC: CBIS) is pleased to announce an opportunity to directly respond to our investors regarding our corporate developments and preclinical initiatives via a 1st Q of 2013 webinar investor call. As we continue to build our team of world-renowned experts to bring CS-S/BCC-1 and CS-TATI-1 through our preclinical investigation and into subsequent human clinical studies to satisfy the FDA regulatory process for market approval both domestically and internationally.
Dr. Robert Melamede, President and CEO, states, "Over the past 3 quarters the company has successfully initiated a strong biomedical research program for the scientific investigation of our lead compound to demonstrate the anti-viral and anti-oncogenic properties based on multiple signaling pathways of cannabinoid therapeutics. In doing so we have initiated the preclinical development and initial product management of CS-TATI-1 and CS-BCC/SC-1 by appointing, Christopher Meenan MS, MBA as Executive VP of Product Research and Development, Ron Sekura PhD as Executive VP of Regulatory Affairs, Roscoe Moore DVM, MPH, PhD, Mariel Selbovitz MPH, Thomas August MD, and Dorothy Bray PhD, to the CBIS SAB team."
Cannabis Science is appointing a Chief Medical Officer and a Chief Scientific Officer to satisfy the regulatory requirements to enter into human clinical studies of CS-TATI-1 and CS-BCC/SC-1 in 2013. The Company expects to also begin initial regulatory review for consideration by federally sponsored clinical research networks in parallel to the Companies own investigations. These appointments will provide the Company with invaluable guidance as it undertakes unprecedented studies towards the commercialization of medicinal cannabinoids.
About Cannabis Science, Inc.
Forward Looking Statements
SOURCE Cannabis Science, Inc.
Latest Cloud Developer Stories
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
SYS-CON Featured Whitepapers
Most Read This Week
Breaking Cloud Computing News